What Is the Treatment of Inflammatory Abdominal Aortic Aneurysm?
Inflammatory abdominal aortic aneurysm (IAAA) is characterised by active peri-aortic inflammation and requires prompt, structured management from the time of diagnosis. A specific first-line treatment protocol exists, with defined clinical and biochemical targets that guide the duration and adjustment of therapy.
Treatment Approach
Management is built around a corticosteroid-based regimen initiated immediately at diagnosis, with the goal of rapidly inducing remission of the inflammatory process. Once the acute phase is controlled, the treatment enters a structured reduction phase. The complete dosing strategy, step-down schedule, and monitoring criteria are detailed in the full protocol.
Partial summary only — full regimen, sequencing, and clinical decision points are available via the link below.
Treatment Goals
The protocol targets complete pain relief and normalisation of erythrocyte sedimentation rate (ESR) within a few weeks of starting treatment, along with measurable reduction of peri-aortic inflammation within 6 to 18 months.
References
DOI: 10.1016/j.ejvs.2023.01.003
- Corticosteroids may be considered a basic treatment that all patients should receive initially.
- As there have been no clinical trials comparing different dosing regimens or treatment duration, the recommended therapy for primary vasculitis may be used; high dose steroid therapy could be initiated immediately after diagnosis to induce remission and, once the acute inflammatory process has been controlled, the dose could be reduced after one year.
- This treatment led to complete pain relief and an ESR within normal limits after a few weeks, and reduction of peri-aortic inflammation within 6–18 months without any recurrence during follow up.
- Used in <10% of patients, corticosteroids led to complete pain relief and a reduction in peri-aortic inflammation within 6–18 months.
View source ↗